Article

Endocrine Month in Review: January 2022

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. January's month in review features new guidelines, a story on women's health, and more.

Editor's note: Clicking the center of a slide will open a new tab with the related content.

Related Videos
Pranav Garimella, MBBS, MPH | Credit: GlobalNewsWire
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Related Content
FDA black and white logo | Credit: US Food and Drug Administration
January 28th 2025

FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease

Abigail Brooks, MA
Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D
January 31st 2025

Diabetes Dialogue: Understanding Semaglutide (Ozempic) in CKD and T2D

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use | Image Credit: University of Maryland
January 24th 2025

Thyroid Cancer Diagnoses Rise in First Year of GLP-1 RA Use

Connor Iapoce
Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics| Image Credit: HCPLive
January 23rd 2025

Diabetes Dialogue: ADA’s 2025 Standards of Care in Diabetes Therapeutics

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Semaglutide 7.2 mg Exhibits 20.7% Weight Loss in Phase 3b STEP UP Trial | Image Credit: Novo Nordisk
January 17th 2025

Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial

Connor Iapoce
HHS Targets 15 Drugs for Medicare Part D Negotiations, Including Semaglutide | Image Credit: HHS
January 17th 2025

HHS Targets 15 Drugs for Medicare Part D Negotiations, Including Semaglutide

Connor Iapoce
© 2025 MJH Life Sciences

All rights reserved.